Celgene: Beat And Raise Again

SUMMIT, NJ (TheStreet) -- Celgene: Beat and raise again, but in-line sales of the cancer drug Revlimid may disappoint. Celgene's adjusted earnings rose by a better-than-expected 36% in the third quarter, driven by strong drug sales and a lower share count. Sales of the multiple myeloma drug Revlimid totaled $820 million, in line with consensus of around $818 million. Like it did after the second quarter, Celgene once again raised financial guidance above current consensus for the remainder of the year to adjusted earnings between $3.78 and $3.80 per share from adjusted earnings in the range of $3.45 to $3.55 per share. ... Click to view a price quote on CELG. Click to research the Drugs industry.

Topics:  summit   nj thestreet    celg   drugs   celgene   revlimid   click   adjusted   sales   earnings   share   million   consensus   quarter   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News